Technology ID
TAB-3842
Development of SARS-CoV-2 Monoclonal Antibodies for Research, Novel Diagnostics, and Thera peutics
E-Numbers
E-002-2021-0
Lead Inventor
Finn, M.G.
Lead IC
CDC
Co-Inventors
Chapman, Asheley
Goldstein, Jason
Zhao, Liangjun
Bagarozzi, Dennis
Chida, Asiya
ICs
CDC
Applications
Vaccines
Therapeutic Areas
Infectious Disease
Development Stages
Discovery
Research Products
Antibodies
This technology includes a large panel of monoclonal antibodies (mAbs) against the spike glycoprotein, capable of recognizing intact SARS-CoV-2 virions with high affinity. Data to support SARS-CoV-2-specific binding include ELISA and label-free (biolayer interferometry) binding measurements using recombinant proteins, immunofluorescence in culture, immunofluorescence staining of tissue from infected patients, and virus neutralization assays. This invention comprises a potentially large panel of mAbs, some of which will be selective for SARS-CoV-2, and others of which will bind multiple members of the coronavirus family. Additional specifications to the invention could include identification of the precise binding site of each antibody.
Commercial Applications
A rapid, sensitive, and specific point-of-care or point-of-entry diagnostic assay for SARS-CoV-2 active infection, as well as useful for the development of antibody-based therapy and of vaccines.
Competitive Advantages
- Diagnostics: These mAbs have the properties of specific detection of SARS-CoV-2 and limited or non-cross-reactivity with related coronavirus members (SARS-1, MERS). These mAbs are high affinity and will provide higher sensitivity than many commercially available and academic mAbs currently available, will allow for maximizing testing method efficiencies, and will have antibodies that recognize all of the recent human coronaviruses for the development of a pan-coronavirus assay.
- Therapeutics: Strongly neutralizing antibodies can be developed as therapeutic agents, delivered either directly or via mRNA for in situ expression.
- Vaccines: The large panel of antibodies that we have will allow us to identify those that neutralize the virus and avoid antibody-dependent enhancement of infectivity. Identifying the epitopes bound by these antibodies will guide the development of targeted immunogens as vaccines.
Licensing Contact: